Biogen-Icahn showdown goes to a vote

Biogen Idec's proxy fight nears its culmination. Shareholders meet today to vote on a slate of directors named by activist investor Carl Icahn, who has called on the board to consider splitting the biotech giant in two. Report

Suggested Articles

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.